Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Transformation to Hodgkin Lymphoma in Chemotherapy-Naïve Patients with Chronic Lymphocytic Leukemia

  • By

  • Paul J. Hampel

  • Ying Huang

  • John N. Allan

  • Seema A. Bhat

  • David Bond

  • Danielle M. Brander

  • John C. Byrd

  • Julio C. Chavez

  • Elise Chong

  • Alexey Danilov

  • Matthew S. Davids

  • Kaitlyn Dvorak-Kornaus

  • Hannah Freedman

  • Nikita Malakhov

  • Matthew Matasar

  • Cecelia Miller

  • Sarah Miller

  • Zulfa Omer

  • Sameer A. Parikh

  • Erin M. Parry

  • Kari G. Rabe

  • Phil Raess

  • Manoj Rai

  • Joanna M. Rhodes

  • Kerry A. Rogers

  • Aditi Saha

  • Jake Schade

  • Geoffrey Shouse

  • Stephen Spurgeon

  • Deborah Stephens

  • Yucai Wang

  • Jennifer A. Woyach

  • Max Yano

  • Adam S. Kittai

  • September 26, 2026

Share

  • 1

    Hodgkin lymphoma transformation occurs in 1 of every 200 patients with chronic lymphocytic leukemia within 10 years after diagnosis.

  • 2

    Patients with Hodgkin lymphoma transformation have longer survival compared to those with diffuse large B-cell lymphoma transformation.

  • 3

    The study identified 43 patients with Hodgkin lymphoma transformation, with 23 having no prior CLL treatment and 20 having prior treatment.

  • 4

    The overall response rate to first-line Hodgkin lymphoma treatment was 79%, with a 67% complete response rate among assessed patients.

  • 5

    The 24-month overall survival rate was 80%, with 86% for patients with no prior CLL treatment and 70% for those with prior treatment.

Original Source(s)

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

  • by Paul J. Hampel, Ying Huang, John N. Allan, Seema A. Bhat, David Bond, Danielle M. Brander, John C. Byrd, Julio C. Chavez, Elise Chong, Alexey Danilov, Matthew S. Davids, Kaitlyn Dvorak-Kornaus, Hannah Freedman, Nikita Malakhov, Matthew Matasar, Cecelia Miller, Sarah Miller, Zulfa Omer, Sameer A. Parikh, Erin M. Parry, Kari G. Rabe, Phil Raess, Manoj Rai, Joanna M. Rhodes, Kerry A. Rogers, Aditi Saha, Jake Schade, Geoffrey Shouse, Stephen Spurgeon, Deborah Stephens, Yucai Wang, Jennifer A. Woyach, Max Yano, Adam S. Kittai

  • September 26, 2026

Related Content

Beyond classical boundaries: rethinking ICU access in acute leukemia

Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale

  • September 18, 2026

  • 2 min
Predictors of Delayed and Omitted Postoperative Radiotherapy After Laryngectomy for pT4 Laryngeal Cancer